Monte Rosa Therapeutics presents data at DDW 2024 on MRT-6160

Monte Rosa Therapeutics announced the company will present preclinical data at Digestive Disease Week, DDW, 2024, being held May 18-21 in Washington, D.C. The data showed that MRT-6160-mediated degradation of VAV1 inhibited disease progression in a T-cell transfer murine model of colitis. Summary of findings: MRT-6160 was shown to inhibit disease progression, prevent colon inflammation, and reduce pro-inflammatory cytokine production in a murine T-cell transfer model of colitis. MRT-6160-mediated murine (m)VAV1 degradation prevented disease progression by 85% compared to vehicle, and also reduced the disease activity index score compared to a standard of care control. Transcriptional analysis of colon tissue showed reduced expression of inflammatory-disease associated T-cell activation, Th17 differentiation, chemokine, and calprotectin subunit genes. MRT-6160 reduced CD4+ T-cell expression of TNF and IL-17A, demonstrating a highly favorable profile compared to active control of anti-TNF antibodies. Additionally, in vitro treatment of human PBMCs with MRT-6160 led to concentration-dependent degradation of human (h)VAV1 in immune cells and inhibited T-cell receptor-mediated expression of pro-inflammatory cytokines and proliferation.